Tranzyme, Inc. (TZYM) announced today that its drug candidate, TZP-102, did not meet its primary efficacy endpoint. Tranzyme’s Phase IIb study was for two doses of TZP-102 taken once daily against a placebo. Even all patients saw a reduction in gastroparesis symptoms after 12 weeks of treatment, the difference between TZP-102 and placebo was minimum […]